854 related articles for article (PubMed ID: 35815933)
41. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
[TBL] [Abstract][Full Text] [Related]
42. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2.
Newman J; Thakur N; Peacock TP; Bialy D; Elrefaey AME; Bogaardt C; Horton DL; Ho S; Kankeyan T; Carr C; Hoschler K; Barclay WS; Amirthalingam G; Brown KE; Charleston B; Bailey D
Nat Microbiol; 2022 Aug; 7(8):1180-1188. PubMed ID: 35836002
[TBL] [Abstract][Full Text] [Related]
43. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
Lyke KE; Atmar RL; Islas CD; Posavad CM; Szydlo D; Paul Chourdhury R; Deming ME; Eaton A; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Archer JI; Crandon S; Zemanek JA; Brown ER; Neuzil KM; Stephens DS; Post DJ; Nayak SU; Suthar MS; Roberts PC; Beigel JH; Montefiori DC;
Cell Rep Med; 2022 Jul; 3(7):100679. PubMed ID: 35798000
[TBL] [Abstract][Full Text] [Related]
44. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162
[TBL] [Abstract][Full Text] [Related]
45. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
[TBL] [Abstract][Full Text] [Related]
46. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
[TBL] [Abstract][Full Text] [Related]
47. Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals.
Park JS; Jeon J; Um J; Choi YY; Kim MK; Lee KS; Sung HK; Jang HC; Chin B; Kim CK; Oh MD; Lee CS
Infect Chemother; 2024 Mar; 56(1):25-36. PubMed ID: 38014726
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
Sieghart D; Hana CA; Dürrschmid C; Heinz LX; Haslacher H; Zlesak M; Piccini G; Manenti A; Montomoli E; Jorda A; Fedrizzi C; Hasenoehrl T; Zdravkovic A; Anderle K; Wiedermann U; Drapalik S; Steinbrecher H; Bergmann F; Firbas C; Jordakieva G; Wagner B; Leonardi M; Pierleoni G; Ballini M; Benincasa L; Marchi S; Trombetta C; Perkmann T; Crevenna R; Zeitlinger M; Bonelli M; Aletaha D; Radner H
J Clin Virol; 2024 Aug; 173():105661. PubMed ID: 38503118
[TBL] [Abstract][Full Text] [Related]
49. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
Lu L; Mok BWY; Chen LL; Chan JMC; Tsang OTY; Lam BHS; Chuang VWM; Chu AWH; Chan WM; Ip JD; Chan BPC; Zhang R; Yip CCY; Cheng VCC; Chan KH; Jin DY; Hung IFN; Yuen KY; Chen H; To KKW
Clin Infect Dis; 2022 Aug; 75(1):e822-e826. PubMed ID: 34915551
[TBL] [Abstract][Full Text] [Related]
50. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
[TBL] [Abstract][Full Text] [Related]
51. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
[TBL] [Abstract][Full Text] [Related]
52. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
Front Immunol; 2022; 13():918896. PubMed ID: 35757764
[TBL] [Abstract][Full Text] [Related]
54. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
Winokur P; Gayed J; Fitz-Patrick D; Thomas SJ; Diya O; Lockhart S; Xu X; Zhang Y; Bangad V; Schwartz HI; Denham D; Cardona JF; Usdan L; Ginis J; Mensa FJ; Zou J; Xie X; Shi PY; Lu C; Buitrago S; Scully IL; Cooper D; Koury K; Jansen KU; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
N Engl J Med; 2023 Jan; 388(3):214-227. PubMed ID: 36652353
[TBL] [Abstract][Full Text] [Related]
55. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A
Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990
[TBL] [Abstract][Full Text] [Related]
56. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
[No Abstract] [Full Text] [Related]
57. Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol.
Campos GRF; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; de Assis JV; Silva TBS; Alves PA; Fernandes GDR; de Oliveira JG; Rahal P; Grenfell RFQ; Nogueira ML
Front Cell Infect Microbiol; 2024; 14():1371695. PubMed ID: 38638823
[TBL] [Abstract][Full Text] [Related]
58. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
59. SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.
Emmelot ME; Vos M; Boer MC; Rots NY; van Els CACM; Kaaijk P
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680141
[TBL] [Abstract][Full Text] [Related]
60. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
